Xcout Intel
AVEO Pharmaceuticals competitors & alternatives
The 12 closest competitors and alternatives to AVEO Pharmaceuticals among pharmaceuticals companies — ranked by similarity to what AVEO Pharmaceuticals actually does, not by market-cap band.
Subscribe to see AVEO Pharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing medicines for cancer and other serious diseases. It is best known for FOTIVDA (tivozanib), an oral VEGFR tyrosine kinase inhibitor approved in the United States for adults with relapsed or refractory advanced renal cell carcinoma after at least two prior systemic therapies.
AVEO Pharmaceuticals at a glance
AVEO Pharmaceuticals is a pharmaceuticals company headquartered in United States. Xcout tracks 12 named people at AVEO Pharmaceuticals, including Mike Ferraresso (President and CEO).
AVEO Pharmaceuticals leadership
- Mike FerraressoPresident and CEO
- Jinchul Jeong (J.J.)Chief Financial Officer
- Edgar BraendleChief Medical Officer
- Barbara A. Fielman, RN, MS, PNPSenior Vice President of Clinical Operations and Site Engagement
- Claudia LebedinskySenior Vice President, Clinical Development
- Danielle HollandSenior Vice President, General Counsel
6 more named people on record for AVEO Pharmaceuticals, with roles, board committees and tenure — see the full roster →
Top 12 AVEO Pharmaceuticals competitors
Ranked by semantic similarity — how close each company is to AVEO Pharmaceuticals by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company based in San Mateo and Redwood City, California, focused on developing and commercializing therapeutic products.
Similar pharmaceuticals company
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Similar pharmaceuticals company
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
Similar pharmaceuticals company
Auven Therapeutics is a privately held specialty pharmaceutical company focused on acquiring, developing, and commercializing late-stage and specialty medicines. It serves patients and healthcare providers through pharmaceutical products developed with industry and clinical partners.
Similar pharmaceuticals company
Deciphera Pharmaceuticals, LLC is a commercial-stage biopharmaceutical company dedicated to delivering transformational medicines, such as QINLOCK, to patients for the treatment of cancer and rare diseases.
Similar pharmaceuticals company
Shorla Pharma (operating as Shorla Oncology) develops and commercializes innovative oncology drugs, focusing on indications where existing treatments are limited, in shortage, or inadequate. The company provides specialized cancer treatments and accessible pharmaceutical options for patients.
Biotechnology & Pharmaceuticals
Lantheus is a radiopharmaceutical-focused company that develops diagnostic and therapeutic products, with a focus on oncology, neurology, and cardiology. The company serves patients and healthcare providers by delivering life-changing science to improve medical outcomes.
Similar pharmaceuticals company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments within cellular metabolism and associated biological domains. Its lead product, PYRUKYND (mitapivat), serves as an activator for both healthy and various mutated forms of the pyruvate kinase (PK) enzyme, targeting the management of hemolytic anemias. Additionally, AG-946, an investigational compound, is currently undergoing Phase I clinical evaluation for hemolytic anemias and other conditions. Established in 2007, Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Similar pharmaceuticals company
Boston Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company that acquires, develops, and advances drug candidates for serious diseases. It works with pharmaceutical and biotechnology partners to bring clinical-stage medicines toward commercialization and serves patients with significant unmet medical needs.
Similar pharmaceuticals company
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Similar pharmaceuticals company
Cao Pharmaceuticals Inc. develops anti-cancer drugs utilizing natural anti-cancer compounds. The company focuses on research, product pipelines, and developing lead drug candidates for cancer treatment.
Biotechnology / Pharmaceuticals
Symphogen, part of the Servier Group, operates as an Antibody Center of Excellence focusing on oncology and immuno-oncology. The company utilizes an antibody discovery and research platform to develop monoclonal antibody therapeutics aimed at improving treatments for cancer patients.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of AVEO Pharmaceuticals and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for AVEO Pharmaceuticalsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →